BridgeBio Pharma, Inc. filings document a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, including financial results, product revenue disclosures, program updates, and formal reports on ATTR-CM, LGMD2I/R9, and achondroplasia development programs.
Its SEC record includes Form 8-K disclosures for results of operations, Regulation FD presentations, clinical and regulatory press releases, material agreements, an at-the-market equity distribution agreement, convertible senior notes, and a board-authorized stock repurchase program. Proxy materials address director elections, executive compensation votes, auditor ratification, incentive plan share reserves, governance structure, and stockholder voting matters.
Jennifer Cook reported proposed sales of Common stock under Rule 144 and recent dispositions. The filing lists a $37,167 share stock option exercise dated 06/24/2026 with cash payment method, and shows prior sales of 2,196 shares on 06/23/2026 for $150,579.72 and 90,240 shares on 06/15/2026 for $6,012,159.04.
This notice records transfers tied to an issuer-directed option exercise and multiple open-market or other dispositions in June 2026. The filing lists Morgan Stanley Smith Barney LLC as the broker/custodian for the securities.
BridgeBio Pharma director Charles J. Homcy reported a routine tax-withholding transaction related to restricted stock units. On vesting of 2,196 RSU-based common shares, 788 shares of BridgeBio Pharma, Inc. common stock were withheld at $66.27 per share to cover his tax obligations.
After this non-market disposition, Homcy directly holds 915,886 shares of BridgeBio common stock. This type of Form 4 event reflects compensation and associated taxes rather than an open-market trade expressing a view on the stock.
Form 144 filing reports a proposed sale of 90,240 shares of Common Stock by Jennifer Cook. The filing shows a disposition dated 06/15/2026 with an aggregate amount of $6,012,159.04. The filing also lists 2,196 shares of restricted stock tied to brokerage arrangements dated 06/20/2026 and an execution/receipt date of 06/23/2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting a proposed sale of 2,196 shares of Common Stock with an effective date of 06/20/2026. The filing also records a prior sale of 2,808 shares on 06/22/2026 for $190,944.
BridgeBio Pharma director Jennifer E. Cook reported option exercises and related share sales. On June 15, 2026, she exercised options to acquire 83,088 shares of common stock at exercise prices of $8.45 and $16.75 per share.
On the same date, she sold 90,240 shares of common stock in open-market transactions at weighted average prices of $66.6153 and $67.1425 per share, under a pre-arranged Rule 10b5-1 sales plan adopted on March 16, 2026. Following these transactions, she directly owned 8,092 shares of BridgeBio Pharma common stock.
BBIO reported proposed sales of Common Stock via Form 144. The filing lists a stock option exercise tied to 83,088 shares dated 06/15/2026 with cash as the consideration method, and two restricted stock lots of 3,576 shares each dated 11/16/2020 and 11/16/2021. The entries are presented as securities to be sold by the reporting holder through the issuer pathway.
BridgeBio Pharma, Inc. reported that family trusts associated with CEO Neil Kumar sold a total of 80,000 shares of common stock in open‑market transactions. The sales occurred on June 4 and 5, 2026 at prices generally between about $65 and $69 per share.
The transactions were executed under a pre‑arranged Rule 10b5‑1 sales plan adopted on March 31, 2025, and were made by the Kumar Haldea Revocable Trust and the Kumar Haldea Family Irrevocable Trust, where Kumar serves as co‑trustee. He also holds 243,327 shares directly and disclaims beneficial ownership of the trust shares beyond any pecuniary interest.
BridgeBio Pharma received a Schedule 13G filing reporting that Farallon-affiliated funds and related persons are beneficial owners of multiple share blocks of Common Stock. The filing lists sizable holdings including Farallon Partners: 10,023,341 shares (5.1%) and Farallon Healthcare Partners Master: 5,918,914 shares (3.0%). Several Farallon funds and affiliated entities report shared voting and dispositive power across holdings; a set of named Farallon individuals are disclosed as managing members with shared investment discretion. The filing is a Section 13 schedule identifying the reporting group and their reported beneficial ownership amounts.
BridgeBio Pharma announced that the FDA has accepted and granted Priority Review to its New Drug Application for oral BBP-418, targeting limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The FDA set a PDUFA target action date of November 27, 2026 and is not currently planning to hold an advisory committee meeting.
If approved, BBP-418 would be the first and only therapy for people living with LGMD2I/R9 and the first approved treatment for any form of limb-girdle muscular dystrophy, addressing a significant unmet need. In the Phase 3 FORTIFY trial, BBP-418 met all primary and secondary endpoints, with treated patients improving on key measures while placebo patients declined.
BBP-418 has Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA and Orphan Drug designation from the EMA. BridgeBio plans additional studies in younger LGMD2I/R9 patients and in related LGMD2M/R13 and LGMD2U/R20 indications.